VERA Vera Therapeutics Inc
Company Analysis
Latest News
🟢 Vera Therapeutics is trading 11% up today in after-hours trading amid broader risk-on market sentiment
Vera Therapeutics is trading at $32.01 (+10.80%) after broader risk-on sentiment likely contributed to the gain. - The S&P 500 rose 0.72% and Nasdaq advanced...
🟢 Vera Therapeutics is trading 5.2% up in after-hours trading amid broader risk-on sentiment
Vera Therapeutics is trading at $30.38, up 5.16% in after-hours trading, in a move consistent with stronger risk appetite; no new company-specific announcement...
🟢 Vera Therapeutics is trading 6% up today in pre-market after narrower-than-expected Q2 loss
Vera Therapeutics is trading 5.65% up at $32.00 after its August 10, 2026, second-quarter update highlighted a narrower-than-expected $1.52-per-share loss. -...
🔴 Vera Therapeutics is trading 4.43% down today after a $109.5 million second-quarter net loss
Vera Therapeutics is trading 4.43% down at $30.18 after investors weighed its August 10 earnings report, which showed a $109.5 million second-quarter net loss...
Vera Therapeutics Beat Estimates and Launched Its First Drug — But Can a $425,000 Kidney Therapy Carve Out Space in a Six-Drug Market?
Shares jumped 6.1% to $33.50 after Vera Therapeutics posted second-quarter results that cleared a low bar while giving investors their first glimpse of life as...
🟢 Vera Therapeutics is trading 6% up in pre-market after second-quarter EPS beat
Vera Therapeutics is trading at $33.50 (+6.08%) after reporting second-quarter EPS of -$1.52 versus the -$1.60 analyst expectation. - Began the TRUTAKNA...
Vera Therapeutics beats second quarter 2026 EPS estimates as TRUTAKNA commercial launch begins
Vera Therapeutics reported a second quarter 2026 net loss of $109.5 million, or $1.52 per share, which narrowed from the $1.60 loss expected by analysts. While...
Vera Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Vera Therapeutics is expected to report a Q2 2026 loss of $1.60 per share on zero revenue, while the stock currently trades at $32.02 against an average...
🟢 Vera Therapeutics is trading 6.43% up today ahead of second-quarter results
Vera Therapeutics is trading at $32.30, up +6.43% during the August 6, 2026 session, with the move potentially reflecting positioning around scheduled...
🔴 Vera Therapeutics is trading 4.1% down today as investors turn cautious ahead of earnings
Vera Therapeutics is trading 4.08% down at $30.95 as investors turn cautious and adjust positions ahead of the company's August 6 earnings report. • The move...
Vera Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Vera Therapeutics is expected to report a Q2 2026 net loss of $1.60 per share on revenue of $1.28 million, with its current stock price of $35.45 trading...
🔴 Vera Therapeutics is trading 4.2% down today amid a broad biotech selloff
Vera Therapeutics is trading at $31.65 (down 4.2%) amid a broad selloff in the biotech sector and mixed overall market conditions. • The move appears driven...
🔴 Vera Therapeutics is trading 5.6% down today despite a broader biotech sector rally
Vera Therapeutics is trading 5.6% down at $33.24 today despite a lack of fresh news and a broader biotech sector rally. • The move appears to be driven by...
🔴 Vera Therapeutics is trading 4.1% down today on profit taking after its post-FDA approval rally
Vera Therapeutics is trading 4.1% down at $36.93 as the stock undergoes short-term profit taking and consolidation following a significant rally earlier this...
🔴 Vera Therapeutics is trading 4.1% down today on profit-taking after its recent FDA-driven rally
Vera Therapeutics is trading 4.1% down at $40.76 as the stock undergoes consolidation following a significant rally earlier in July. • The stock's recent...
🟢 Vera Therapeutics is trading 4% up today following recent FDA approval of its IgA nephropathy drug
Vera Therapeutics is trading 4% up at $43.16 as momentum continues from the recent FDA accelerated approval of its IgA nephropathy drug, atacicept...
Vera Therapeutics downgraded to Sell, facing stiff competition for TRUTAKNA
Analysts downgraded Vera Therapeutics from Hold to Sell following the FDA's accelerated approval of its IgAN treatment, TRUTAKNA. The report cites a crowded...
🔴 Vera Therapeutics is trading 5.4% down today on profit-taking after TRUTAKNA FDA approval
Vera Therapeutics is trading 5.38% down today at $40.16 following a sharp post-approval pullback as investors lock in gains. • The decline is characterized as...
🔴 VERA is trading 4.9% down today on profit-taking following its FDA approval rally
VERA is trading at $40.86 (4.9% down) as investors take profits following a sharp rally sparked by the FDA’s accelerated approval of its IgA nephropathy drug,...
🔴 VERA is trading 4.6% down today on profit-taking after FDA approval surge
VERA is trading at $41.00 (4.6% down) in pre-market as investors lock in gains following the FDA's accelerated approval of its IgA nephropathy drug, atacicept...